Checkpoint Inhibitor
Nivolumab After Bone Marrow Transplant for Sarcoma
This trial is testing if the investigational drug Nivolumab is safe to take after a "half-matched" bone marrow transplant, and if it helps prevent or delay relapse or progression of sarcomas.
Popular Filters
Trials for Soft Tissue Sarcoma Patients
Kinase Inhibitor
Turalio for Leukemia
This trial is testing a drug called PLX3397 to see if it can help treat certain types of cancer. Eligible participants will take the drug once daily for a 28-day cycle, and will have various tests and procedures throughout the study.
Hu3F8 PET Imaging for Brain Cancer
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Trials for Rhabdomyosarcoma Patients
Kinase Inhibitor
Turalio for Leukemia
This trial is testing a drug called PLX3397 to see if it can help treat certain types of cancer. Eligible participants will take the drug once daily for a 28-day cycle, and will have various tests and procedures throughout the study.
Hu3F8 PET Imaging for Brain Cancer
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Trials for Metastatic Patients
Hu3F8 PET Imaging for Brain Cancer
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Radiation
IGIMRT Dosing Schedules for Cancer Spread to Bone/Spine
This trial is studying two ways of giving high-dose radiation for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. One way is 27 Gy in three fractions (3 days) and the other is 24 Gy in one fraction (1 day).
CAR T-cell Therapy
CAR T-Cell Therapy for Sarcoma
This trial is testing a new cancer treatment that uses patients' own immune cells. Researchers will insert a new gene into the cells that will make them better at fighting the cancer. The cells will be given to patients after they have received chemotherapy, which should help the cells to better fight the cancer.
Trials With No Placebo
Kinase Inhibitor
Turalio for Leukemia
This trial is testing a drug called PLX3397 to see if it can help treat certain types of cancer. Eligible participants will take the drug once daily for a 28-day cycle, and will have various tests and procedures throughout the study.
Hu3F8 PET Imaging for Brain Cancer
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
View More Related Trials
Frequently Asked Questions
Introduction to sarcoma
What are the top hospitals conducting sarcoma research?
When it comes to cutting-edge clinical trials focused on sarcoma, several top hospitals are leading the way. Memorial Sloan Kettering Cancer Center in New york stands out with an impressive 17 active sarcoma trials and a remarkable record of 89 completed trials throughout its history. Since conducting their first sarcoma trial in 1993, this renowned institution has been at the forefront of innovative research for this rare form of cancer. Meanwhile, Massachusetts General Hospital in Boston has also made significant contributions with six ongoing sarcoma trials and a total of 38 completed trials since their pioneering investigation started in 1999.
Heading west to Los Angeles, UCLA/Jonsson Comprehensive Cancer Center is another major player in the field. With six active clinical trials focusing on sarcoma and a cumulative count of fifteen past studies addressing this disease since recording their inaugural trial in 1999, they have become instrumental in advancing our understanding and treatment options for those affected by sarcomas.
In Chicago, Northwestern University Medical Center has emerged as a formidable force against this type of cancer as well. They currently have five active sarcoma trials underway and can proudly look back on thirty-one prior investigations conducted since initiating their first recorded trial dedicated to tackling sarcomas back in2009. Lastly but not leastly still contributing important insights into the worldof potential treatmentsand solutions; Dana Farber Cancer Institute located once again InBoston offers five current open-minded experiments conducing grounds breaking work that promised new discoveries about Sarcomas' nature after participating alongside32 previous examinations from starting from around fourteen short years ago until2007
These hospitals represent beacons of hope for those diagnosed with rare forms of cancer like sarcoma. Through relentless dedication to research and innovation, these institutions continue to push boundaries forward while seeking more effective treatments for patients worldwide who are afflicted by these challenging diseases
Which are the best cities for sarcoma clinical trials?
When it comes to sarcoma clinical trials, several cities stand out as leading hubs for research and development. New york City boasts 39 active trials studying treatments like INBRX-109 and Selumetinib. Los Angeles and Chicago both have 30 ongoing studies focusing on drugs such as Doxorubicin Hydrochloride, Paclitaxel, and others. In Boston, Massachusetts, there are 24 active trials exploring Olaparib, CPI-006, TP-1287, among other promising interventions. Lastly, Houston in Texas offers 15 active trials investigating therapies like Autologous HER2-specific T cells and GD2 T cells. These cities provide individuals with access to cutting-edge sarcoma clinical trials that pave the way for advancements in treatment options for this challenging cancer type while offering hope for better outcomes.
Which are the top treatments for sarcoma being explored in clinical trials?
Exciting progress is being made in the field of sarcoma treatment, with several top contenders emerging from ongoing clinical trials. Stereotactic Radiosurgery has caught researchers' attention, currently undergoing testing in two active trials and showcasing its potential through four all-time sarcoma trials since 2004. Another promising option is Olaparib, showing promise with two active and seven all-time sarcoma trials since its debut in 2012. Pembrolizumab also joins the ranks as a front-runner, participating in two current studies while making waves with an impressive 26 all-time sarcoma trials starting from 2014 onwards. Lastly, Cabozantinib demonstrates significant potential by engaging in two active and eight total sarcoma trials beginning back in 2013. With each trial bringing us closer to breakthroughs, hope shines brighter for patients battling this complex disease.
What are the most recent clinical trials for sarcoma?
Recent clinical trials offer optimism for patients with sarcoma, a challenging form of cancer. One such trial is CRD3874-SI, which explores the potential benefits of this treatment in early phases. Additionally, researchers are investigating the use of SNS-101 alone or in combination with cemiplimab through Phase 1 and Phase 2 studies to determine their efficacy against sarcoma. Another promising study focuses specifically on dedifferentiated liposarcoma/DDLPS participants and evaluates potential treatment options in Phase 2. Furthermore, XmAb23104 is being investigated in a Phase 2 trial as a potential therapy for sarcoma. Lastly, KVA12123 combined with pembrolizumab shows promise as it undergoes further exploration in both Phase 1 and Phase 2 trials. These ongoing investigations hold great promise for advancing our understanding and treatment options for individuals battling sarcomas.
What sarcoma clinical trials were recently completed?
In recent years, several clinical trials have been completed to advance the understanding and treatment of sarcoma. Notably, in September 2021, a trial sponsored by Rafael Pharmaceuticals Inc. investigated the combination of CPI-613 and Hydroxychloroquine for this type of cancer. Prelude Therapeutics also completed a trial in August 2021 focusing on PRT1419 therapy. Additionally, Dana-Farber Cancer Institute concluded their study on Cabozantinib in December 2020. These endeavors reflect the ongoing efforts to develop innovative approaches against sarcoma and offer hope for patients grappling with this challenging disease.